Change Point Analysis for Detecting Vaccine Safety Signals

Change Point Analysis for Detecting Vaccine Safety Signals

It is important to detect signals of abrupt changes in adverse event reporting in order to notice public safety concerns and take prompt action, especially for vaccines under national immunization programs. In this study, we assessed the applicability of change point analysis (CPA) for signal detect...

Full description

Bibliographic Details
Main Authors:	Seung-Hun You, Eun Jin Jang, Myo-Song Kim, Min-Taek Lee, Ye-Jin Kang, Jae-Eun Lee, Joo-Hyeon Eom, Sun-Young Jung
Format:	Article
Language:	English
Published:	MDPI AG 2021-03-01
Series:	Vaccines
Subjects:	change point analysis vaccines data mining pharmacovigilance adverse events signal detection
Online Access:	https://www.mdpi.com/2076-393X/9/3/206

Similar Items

Comparative Safety Profiles of Sedatives Commonly Used in Clinical Practice: A 10-Year Nationwide Pharmacovigilance Study in Korea
by: Yeo-Jin Choi, et al.
Published: (2021-08-01)

Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System
by: Yamin Shu, et al.
Published: (2022-06-01)

Reporting of adverse events for marketed drugs: Need for strengthening safety database
by: Aditi Anand Apte
Published: (2016-01-01)

A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system
by: Bin Zhao, et al.
Published: (2024-03-01)

A real-world disproportionality analysis of mesalazine data mining of the public version of FDA adverse event reporting system
by: Mingdi Liu, et al.
Published: (2024-01-01)

Adverse events in patients with advanced urothelial carcinoma treated with erdafitinib: a retrospective pharmacovigilance study
by: Tengfei Yuan, et al.
Published: (2023-11-01)

Safety of COVID-19 vaccines
by: B. K. Romanov
Published: (2022-12-01)

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
by: Yamin Shu, et al.
Published: (2022-10-01)

Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system
by: Tingting Jiang, et al.
Published: (2022-12-01)

Challenges in Assessing COVID-19 Vaccines Safety Signals—The Case of ChAdOx1 nCoV-19 Vaccine and Corneal Graft Rejection
by: Christelle Bizimungu, et al.
Published: (2023-05-01)

Real-World Safety Profile of Biologics Used in Rheumatology: A Six-Year Observational Pharmacovigilance Study in the Calabria Region
by: Agnese Gagliardi, et al.
Published: (2022-10-01)

New Adverse Drug Reaction Signals from 2017 to 2021—Genuine Alerts or False Alarms?
by: Yoon Kong Loke, et al.
Published: (2024-02-01)

A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data
by: Qilin Zhang, et al.
Published: (2023-08-01)

Safety monitoring of COVID-19 vaccines: February 26, 2021, To June 4, 2022, Republic of Korea
by: Yeon-Kyeng Lee, et al.
Published: (2023-10-01)

Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system
by: Rui Xiong, et al.
Published: (2023-09-01)

Detection of potential safety signals related to the use of remdesivir and tocilizumab in the COVID era during pregnancy, resorting to open data from the FDA adverse event reporting system (FAERS)
by: Beatriz Marinho Silva Romão, et al.
Published: (2024-01-01)

Vaccines Safety in Children and in General Population: A Pharmacovigilance Study on Adverse Events Following Anti-Infective Vaccination in Italy
by: Niccolò Lombardi, et al.
Published: (2019-08-01)

Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database
by: Junwei Wang, et al.
Published: (2024-03-01)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
by: Yamin Shu, et al.
Published: (2023-05-01)

Patient safety discourse in a pandemic: a Twitter hashtag analysis study on #PatientSafety
by: Olena Litvinova, et al.
Published: (2023-11-01)

Drug-induced QT prolongation and torsade de pointes: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
by: Dongxuan Li, et al.
Published: (2023-12-01)

A real-world study of antifibrotic drugs-related adverse events based on the United States food and drug administration adverse event reporting system and VigiAccess databases
by: Menglin He, et al.
Published: (2024-02-01)

Pharmacological Evaluation of Signals of Disproportionality Reporting Related to Adverse Reactions to Antiepileptic Cannabidiol in VigiBase
by: Fabrizio Calapai, et al.
Published: (2023-10-01)

Adverse reactions by antibiotics and non-steroidal anti-inflammatory drugs
by: Karen Orellana, et al.
Published: (2022-03-01)

Identifying barriers to report adverse drug reactions using the Delphi method: Experience from an institute of national importance of India
by: Bikash Ranjan Meher, et al.
Published: (2022-01-01)

Is Omalizumab Related to Ear and Labyrinth Disorders? A Disproportionality Analysis Based on a Global Pharmacovigilance Database
by: Hyeon Tae Park, et al.
Published: (2022-10-01)

Detection and evaluation of signals for immune-related adverse events: a nationwide, population-based study
by: Eo Jin Kim, et al.
Published: (2024-01-01)

Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system
by: Jing Huang, et al.
Published: (2020-09-01)

A Real-World Data Driven Pharmacovigilance Investigation on Drug-Induced Arrhythmia Using KAERS DB, a Korean Nationwide Adverse Drug Reporting System
by: Chaerin Go, et al.
Published: (2023-11-01)

Safety of SGLT2 Inhibitors: A Pharmacovigilance Study from 2013 to 2021 Based on FAERS
by: Xiang Zhou, et al.
Published: (2021-12-01)

Post-marketing safety evaluation of lurbinectedin: a pharmacovigilance analysis based on the FAERS database
by: Zhao Li, et al.
Published: (2024-03-01)

Improved drug safety through intensive pharmacovigilance in hospitalized pediatric patients
by: Alan O. Vázquez-Alvarez, et al.
Published: (2017-12-01)

Real-Life Active Surveillance of a Naphazoline/ Hypromellose Fixed Combination’s Safety Profile in Peruvian Population
by: Contreras-Salinas H, et al.
Published: (2021-10-01)

Pharmacovigilance in Brazil: The Government Monitoring of Adverse Events Reported from COVID-19 Vaccine—A Narrative Review
by: Mariana Carvalho de Moraes, et al.
Published: (2024-02-01)

Awareness of Digital Reporting of Adverse Drug Events among Health Care Professionals
by: Shweta Sharma, et al.
Published: (2023-09-01)

Adverse event reporting practices in drug-resistant tuberculosis facilities across South Africa
by: Razia Gaida, et al.
Published: (2023-12-01)

Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS)
by: Lin Zhang, et al.
Published: (2023-11-01)

Adverse events in patients with leprosy on treatment with thalidomide
by: Paula Lana de Miranda Drummond, et al.
Published: (2019-04-01)

Toxicity spectrum of immunotherapy in advanced lung cancer: A safety analysis from clinical trials and a pharmacovigilance system
by: Yi-Dan Yan, et al.
Published: (2022-08-01)

Is pitolisant safe for clinical use? A retrospective pharmacovigilance study focus on the post‐marketing safety
by: Cheng Jiang, et al.
Published: (2024-02-01)